SelectQuote's Fiscal First Quarter 2027 Earnings Call - SELECTQUOTE INC

Financial Performance:

• Consolidated Q1 FY2027 revenue was $280 million, a 15% year-over-year decline; adjusted EBITDA loss narrowed to $17 million, a $15 million YoY improvement (vs. a 56% improvement in Healthcare Services segment EBITDA to $11 million).
• Senior segment revenue dropped to $51 million due to a deliberate reduction in agent headcount; Senior adjusted EBITDA loss improved $9 million YoY to $12 million.
• Healthcare Services revenue fell 16% to $186 million primarily due to the Inflation Reduction Act (IRA) impacting drug pricing; however, EBITDA margins expanded as manufacturer reimbursements offset lower drug prices, resulting in a 60% increase in EBITDA per SelectRx member to $108.
• Life Insurance segment revenue declined $4 million to $43 million, yet adjusted EBITDA rose 31% YoY to $7 million, driven by 17% margins and 500 basis points of margin expansion.
• Company reaffirmed guidance for at least $60 million in operating cash flow for FY2027, citing improved capital efficiency and the ability to reduce high-cost debt.
• Announced a proposed reverse stock split to maintain NYSE listing, clarifying it has no material economic impact and no capital raise is intended.

Guidance and Future Outlook:

• Management expects the Medicare Advantage (MA) industry to reach an inflection point soon as carriers right-size and align benefits with profitability, positioning SelectQuote to accelerate top-line growth.
• For FY2027, the focus remains on profitability and cash flow generation; growth is contingent on carrier partners accelerating policy growth efforts.
• Outlook for Healthcare Services includes a goal to double segment margins in FY2027, driven by the new Pharmacy Management System (PMS) and consolidation of scripts through the Olathe, Kansas facility.
• Management indicated a multi-year path toward paying cash dividends once cash flow levels stabilize at current or higher trajectories.
• While no specific FY2028 guidance is provided, the company projects continued revenue and cash flow growth as the MA market environment improves.

Business Segments and Product Lines:

• Senior (Medicare Advantage): Early AEP results are strong with high engagement; the strategy prioritizes retention of terminated/beneficiary-disrupted plans using a high-mix of tenured agents (approx. 2x productivity of new agents).
• Healthcare Services (SelectRx): Scaling profitability despite revenue headwinds; implementing AI-driven automated enrollment (20% faster) and the new PMS to integrate onboarding, fulfillment, and shipping.
• Life Insurance: Final expense delivered strong margins with transfer synergies from Senior; Term Life showed modest growth with stable margins.
• Technology Integration: Over $30 million in permanent run-rate costs removed; AI now screens 1/3 of calls, analyzes all agent calls for coaching, and handles administrative enrollment, freeing agents for complex needs analysis.
• Facility Efficiency: The Olathe, Kansas facility operates at 30% higher efficiency than legacy sites, with plans to increase the percentage of scripts shipped from there.

Market and Competitive Landscape:

• The MA market is currently defined by disruption, with carriers implementing planned terminations and benefit restructuring; SelectQuote expects 30% recapture rates (improving on last year's 30%) for terminated policies.
• Carriers are showing improved financial health (better MLRs) and are shifting focus from pure volume to profitability and long-term viability, which aligns with SelectQuote's strategic focus.
• Increased carrier interest in Special Needs Plans (SNPs, DSNPs, HMOs) is viewed as a tailwind for the company's platform and SelectRx enrollments.
• SelectQuote maintains its position as the leading direct-to-consumer MA distributor, leveraging its agent network and technology to capture market share during periods of high plan churn.

Risks and Challenges:

• Regulatory Headwinds: The Inflation Reduction Act continues to suppress top-line revenue in the Healthcare Services segment due to lower drug prices, though EBITDA impact is mitigated.
• Market Volatility: Continued dynamic conditions in the Medicare Advantage sector, including carrier right-sizing and benefit pullbacks, constrain top-line growth opportunities.
• Operational Complexity: Transferring existing members to the new Olathe facility involves a complicated transfer process that will take time to fully realize.
• Hiring Constraints: Deliberate reduction in new agent hiring limits the ability to scale volume rapidly, though existing tenured agents are compensated for efficiency.

Management Commentary and Tone:

• Tone was confident and resilient; management emphasized "operational excellence" and "cash flow efficiency" as the core differentiators during a challenging industry cycle.
• CEO Tim Danker highlighted the success of the "North Star" strategy to leverage AI and technology to maximize shareholder value.
• CFO Ryan Clement reinforced the durability of the model, noting that profitability improvements were achieved despite a "down cycle" and that the balance sheet is strengthened for future capital allocation.
• Management expressed optimism that the current MA disruption is nearing a "tail end," paving the way for a return to growth.

Analyst Questions and Answers:

• Revenue Decline Drivers: Clarified that Senior revenue drop was intentional (smaller agent force) and Healthcare Services drop was IRA-driven; profitability remained strong in both.
• AEP Volume & Recapture: Confirmed early AEP engagement is high; while a smaller agent force may impact total volumes, high productivity and efficiency aim to improve upon last year's recapture rates.
• LTV Growth: Attributed 16% LTV growth to a mix of CMS commission rate increases and carrier repricing (keramics).
• Plan Terminations & Commissions: Carriers are focusing on profitable plans; commission environments are stabilizing due to better carrier financial health and plan sustainability.
• SelectRx PMS Timeline: New members are already enrolling into the Kansas facility; retro-fitting legacy facilities will follow, with a "quick" visibility on volume migration expected.
• IRA Impact Duration: The IRA is a multi-year program; while top-line pressure persists, bottom-line impact is minimal due to reimbursements; a "clean year-over-year" comparison is difficult to pinpoint immediately due to staggered drug introductions.
• Dividend Policy: No immediate plan to pay cash dividends in FY2027, but a path exists in the multi-year model as cash flow grows.

Other Key Points:

• SelectQuote is leveraging voice AI to transcribe and score every agent call, reducing ramp time for new agents and improving coaching.
• The new Pharmacy Management System (PMS) is viewed as a critical "missing link" to drive growth in the healthcare services segment.
• Life Insurance benefits from cross-sell synergies, specifically transfer rates from the Senior business generating leads at no incremental acquisition cost.
• Management reiterated that the stock is significantly undervalued and that the reverse stock split is a procedural step to maintain exchange listing, not a signal of financial distress.